Controversy and Progress in Alzheimers Disease - FDA Approval of AducanumabNEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Initial Highly Effective Therapy for MSNeurol 95:1114-1116, Wallin, M.T., 2020